United Therapeutics Corporation (NASDAQ:UTHR – Get Free Report) CEO Martine Rothblatt sold 9,500 shares of the business’s stock in a transaction dated Monday, November 16th. The shares were sold at an average price of $587.74, for a total transaction of $5,583,530.00. Following the completion of the transaction, the chief executive officer directly owned 324,443 shares of the company’s stock, valued at $190,688,128.82. The trade was a 2.84% decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website.
United Therapeutics Stock Performance
Shares of UTHR stock opened at $559.10 on Friday. The company’s 50-day simple moving average is $548.85 and its 200-day simple moving average is $538.52. The stock has a market capitalization of $23.81 billion, a price-to-earnings ratio of 21.10, a PEG ratio of 3.84 and a beta of 0.49. United Therapeutics Corporation has a one year low of $455.63 and a one year high of $614.23.
United Therapeutics (NASDAQ:UTHR – Get Free Report) last announced its earnings results on Wednesday, November 4th. The biotechnology company reported $5.71 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $6.01 by ($0.30). The company had revenue of $832.50 million for the quarter, compared to analyst estimates of $781.14 million. United Therapeutics had a return on equity of 19.18% and a net margin of 38.61%. The firm’s revenue for the quarter was up 4.1% on a year-over-year basis. During the same period last year, the firm earned $7.16 earnings per share. As a group, research analysts forecast that United Therapeutics Corporation will post 25.08 EPS for the current year.
Institutional Inflows and Outflows
A number of large investors have recently bought and sold shares of UTHR. Callan Family Office LLC bought a new position in shares of United Therapeutics during the 2nd quarter worth about $1,217,000. Andra AP fonden raised its stake in shares of United Therapeutics by 33.5% during the 2nd quarter. Andra AP fonden now owns 34,904 shares of the biotechnology company’s stock worth $18,912,000 after purchasing an additional 8,760 shares in the last quarter. Canada Pension Plan Investment Board acquired a new position in shares of United Therapeutics in the second quarter valued at $3,359,000. Partners Capital Investment Group LLP acquired a new stake in United Therapeutics in the 2nd quarter worth about $1,691,000. Finally, Palo Alto Investors LP bought a new position in shares of United Therapeutics in the 2nd quarter valued at $33,911,514. Institutional investors and hedge funds own 94.08% of the company’s stock.
Analyst Ratings Changes
A number of analysts have recently issued reports on the company. BTIG Research raised their price objective on United Therapeutics from $728.00 to $768.00 and gave the company a “buy” rating in a research report on Wednesday, November 4th. Weiss Ratings lowered United Therapeutics from a “buy (b-)” rating to a “hold (c+)” rating in a research note on Monday, November 9th. JPMorgan Chase & Co. cut their price objective on United Therapeutics from $710.00 to $695.00 and set an “overweight” rating for the company in a report on Wednesday, October 28th. Raymond James Financial set a $720.00 price objective on shares of United Therapeutics in a research report on Wednesday, November 4th. Finally, Royal Bank Of Canada raised their price objective on shares of United Therapeutics from $697.00 to $725.00 and gave the company an “outperform” rating in a research note on Thursday, November 5th. Twelve analysts have rated the stock with a Buy rating, three have assigned a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat, United Therapeutics presently has an average rating of “Moderate Buy” and an average price target of $676.40.
Read Our Latest Analysis on United Therapeutics
United Therapeutics Company Profile
United Therapeutics is a biotechnology company that develops and commercializes treatments for serious diseases, with a primary focus on pulmonary arterial hypertension (PAH). Its therapies include treprostinil products delivered by injection, inhalation, or oral tablet, marketed under brands including Remodulin, Tyvaso, and Orenitram. The company also markets Unituxin, a treatment for high-risk neuroblastoma. Founded in 1996 by Martine Rothblatt, United Therapeutics is also pursuing technologies intended to address the shortage of transplantable organs.
Recommended Stories
- Five stocks we like better than United Therapeutics
- Grand Theft Auto VI Arrives: Why Take-Two Is a Waiting Game
- Greg Abel Makes His Next Moves: Inside Berkshire’s Q3 Portfolio
- Walmart Earnings Change the Narrative as Digital Growth Lifts Outlook
- Whatever Happens to Copper Next, These 3 Investments Offer Different Ways to Play It
Receive News & Ratings for United Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for United Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
